Abstract: Athletic performance may be improved by administering a composition comprising galanthamine as an active ingredient to an athlete before and during sports activities. Also provided is an herbal sports performance composition comprising whole plant extract of Leucojum aestivum.
Abstract: The present invention is directed to a compound of the formula (I):
and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
April 22, 2003
Assignee:
Pfizer Inc.
Inventors:
Anton Franz Joseph Fliri, Todd William Butler, Randall James Gallaschun
Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I)
or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
Type:
Grant
Filed:
June 15, 2000
Date of Patent:
April 15, 2003
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. B. Calvello, David M. Zawrotny
Abstract: The invention relates to pyridopyranoazepine derivatives, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment or prevention of disorders associated with a dysfunction of the nicotine receptors.
Abstract: Analogs of galanthamine and lycoramine are useful in modulating nicotinic receptors in humans and other animals. Modulation of such receptors is useful in treatment and/or prevention of a number of conditions including treatment of attention disorders, assistance in giving up smoking, and in treatment of Parkinson's disease.
Abstract: The present invention provides diazabicyclooctane derivatives of formula (I):
and pharmaceutically acceptable salts thereof, wherein the group represents
R1 and R2 are selected independently from H, (C1-C6)alkyl, (C1-C6)fluoroalkyl, halogen (e.g., F.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
March 11, 2003
Assignee:
Pfizer Inc
Inventors:
Anton Franz Joseph Fliri, Randall James Gallaschun
Abstract: The subject matter of the present invention concerns a process for the isolation of the alkaloid galanthamine; the galanthamine itself which has been produced according to this process; the use of the galanthamine thus produced in galenic preparations; and the galanthamine thus produced for treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence.
Type:
Application
Filed:
September 12, 2002
Publication date:
January 16, 2003
Inventors:
Thomas Hille, Hans-Rainer Hoffmann, Mirko Kreh, Rudolf Matusch
Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacylic compounds. The present invention relates in particular to five-membered heteroaromatic olefinic azacyclic compounds and five-membered heteroaromatic acetylenic azacylic compounds, including isoxazolyl olefinic cycloalkylamines and isoxazolyl acetylenic cycloalkylamines.
Abstract: The present invention provides a pyrrolidine compound of the formula (I)
wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.
Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.
Type:
Application
Filed:
October 5, 2001
Publication date:
April 18, 2002
Inventors:
Gurmit Grewal, Anna Toy-Palmer, Xiong Cai, George Mark Latham
Abstract: The present invention relates to diazabicyclic compounds, preferably to N-aryl diazabicyclic compounds. Of particular interest are 2-pyridyl diazabicyclic compounds, such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. Other exemplary compounds of the present invention include: (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1 ]heptane, (1S,4S)-2-(5-(3,4-dimethoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1 ]heptane, and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane. The present invention also relates to prodrug derivatives of the compounds of the present invention.
Type:
Application
Filed:
May 24, 2001
Publication date:
January 31, 2002
Inventors:
Craig Harrison Miller, Gary Maurice Dull, Lan Miao, Dwo Lynm, Jeffrey Daniel Schmitt, Thomas Jeffrey Clark
Inventors:
Youssef L. Bennani, Lawrence A. Black, Wesley J. Dwight, Ramin Faghih, Robert G. Gentles, Huaqing Liu, Kathleen M. Phelan, Anil Vasudevan, Henry Q. Zhang
Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.
Type:
Grant
Filed:
October 17, 2000
Date of Patent:
November 27, 2001
Assignee:
UCB, S.A.
Inventors:
Gurmit Grewal, Anna Toy-Palmer, Xiong Cai, George Mark Latham
Abstract: The present invention relates to new 2-Phenyl-1-[(2-Aminoethoxy)-Benzyl]-Indole compounds which are usefuil as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utiig these compounds, which have the general structures below: 1
Type:
Application
Filed:
February 8, 2001
Publication date:
September 13, 2001
Inventors:
Chris P. Miller, Michael D. Collini, Bach D. Tran, Arthur A. Santilli
Abstract: The present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizoaffective disorder, and schizophreniform disorder in a patient using a Compound (I).
Type:
Grant
Filed:
April 3, 2000
Date of Patent:
September 4, 2001
Assignee:
Eli Lilly and Company
Inventors:
Charles H. Mitch, Per Sauerberg, Harlan E. Shannon